Abstracts tagged "neurology and pain"

Abstract Number: 2228 • 2017 ACR/ARHP Annual Meeting
Involvement of Receptor Tyrosine Kinase a Signaling in Rhumatoid Arthritis Using Trka/C Knock-in Mice: A Multimodal Approach
Lauriane Delay¹, Julie Barbier¹, Ludivine Boudieu¹, Denis Ardid¹, Arnaud Briat², Philippe Auzeloux², Elisabeth Moit-Noirault², Aziz Moqrich³ and Fabien Marchand¹, ¹Inserm U1107 NeuroDol, Université Clermont Auvergne, Clermont-Ferrand, France, ²4UMR 1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France, ³UMR 6216 CNRS-Université de la Méditerranée, Institut de Biologie du Développement de Marseille Luminy, Marseille, France
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease very commonly associated with chronic pain which is often resistant to currents analgesics. Targeting Nerve Growth Factor…
Abstract Number: 1095 • 2014 ACR/ARHP Annual Meeting
Treatment of Fibromyalgia with Neurostimulation: A Randomized, Double-Blinded, Sham-Controlled Trial
R Michael Gendreau^1,2, Donald Deering³, Judith Gendreau¹ and Jeffrey Hargrove⁴, ¹Gendreau Consulting, LLC, Poway, CA, ²Cerephex Corporation, Los Altos, CA, ³St. Joseph Mercy Oakland, Pontiac, MI, ⁴Research & Development, Cerephex Corporation, Los Altos, CA
Background/Purpose: NeuroPoint is a medical device designed to provide noninvasive brain stimulation using a proprietary approach to deliver very low energy levels to deep brain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].